An experimental gene therapy based on the VERVE-102 injection has shown in a clinical study that it can reduce "bad" cholesterol (LDL) by up to 62% for a year, offering hopes for a long-term treatment that could replace the need for daily administration of traditional medications, with no severe safety issues observed so far. (translated)
















